Skadden, Arps, Slate, Meagher & Flom and Gibson, Dunn & Crutcher have taken on lead roles in New Jersey-headquartered pharmaceutical group Merck & Co.'s $3 billion acquisition of EyeBio, an ophthalmology-focused drug development company in the U.K.